Multicenter Randomized Open-label Controlled Study to Investigate Treatment Response of IV Injectafer vs Oral Iron to Baseline Hepcidin Levels in Patients With Iron Deficiency Anemia Secondary to Inflammatory Bowel Disease or Gastric Bypass

Trial Profile

Multicenter Randomized Open-label Controlled Study to Investigate Treatment Response of IV Injectafer vs Oral Iron to Baseline Hepcidin Levels in Patients With Iron Deficiency Anemia Secondary to Inflammatory Bowel Disease or Gastric Bypass

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 30 Mar 2017

At a glance

  • Drugs Ferric carboxymaltose (Primary) ; Ferrous sulfate
  • Indications Inflammatory bowel diseases; Iron deficiency anaemia
  • Focus Therapeutic Use
  • Sponsors Luitpold Pharmaceuticals
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 25 Jan 2017 Planned End Date changed from 1 Dec 2016 to 1 Oct 2017.
    • 22 Jul 2016 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top